Key messages

  • SCIg is a preparation of human immunoglobulin for subcutaneous use (an injection in which the needle is inserted just under the skin).
  • Under the national blood arrangements SCIg is only approved for specific patients. Health services participating in the national SCIg programs are required to meet specified governance arrangements.
  • In 2018-19, the SCIg Access Program will provide Victorian public health services, $680 per patient per quarter.

SCIg is a prescription only medication that may be used in an admitted patient or outpatient setting1.

Subcutaneous immunoglobulin (SCIg) is a solution of human plasma proteins and in particular IgG antibodies with a broad spectrum of antibody activity. SCIg is prepared from large pools of human plasma and contains the typical IgG antibodies found in the normal population2.

Approved access conditions for SCIg

SCIg is only approved for patients with a medical condition3:

  1. Where there is support for use cited in the Criteria for the clinical use of intravenous immunoglobulin in Australia, namely:
    • primary immunodeficiency diseases with antibody deficiency
    • specific antibody deficiency
    • acquired hypogammaglobulinaemia secondary to haematological malignancies (chronic lymphocytic leukaemia, multiple myeloma, non-Hodgkin lymphoma and other relevant malignancies, and post-haemopoietic stem cell transplantation)
    • secondary hypogammaglobulinaemia (including iatrogenic immunodeficiency)
  2. Being treated by a clinical specialist within a hospital based SCIg program (see below), where the hospital provides access to all resources and takes full accountability for the management and use of the SCIg product, at no additional cost to patients, and
  3. Following a patient-specific SCIg request submitted to, and authorised by, the Australian Red Cross Blood Service (Blood Service).

Funding arrangements

The department has outlined its commitment to funding SCIg in the department's Policy and funding guidelines 2018 Volume 2: Health operations 2018–19 Chapter 1: Overview, key changes and new initiatives document. Refer to section – Subcutaneous immunoglobulin (page 64).

The Department will fund public health services $680 per quarter for each patient that is being supplied SCIg.

This should cover ongoing costs associated with SCIg service delivery including- patient training, staffing costs, consumables, pumps and dispensing fees.

Funding will be provided to the 'Administering Facility' that is registered with the National Blood Authority and dispenses the SCIg. Blood STAR which is Australia’s immunoglobulin management system will be used as the data source for hospital funding.

Additional resources

The Blood Matters team has a SCIg project nurse resource to assist in the state-wide rollout of SCIg in Victoria.

The key objective of this resource is to support local health services to develop appropriate policies and guidelines that follow requirements outlined by the National Blood Authority.

More information on SCIg can be found at the National Blood Authority website3.


Hospital Circular 10/2013

Australian Red Cross Blood Service  

National Blood Authority


SCIg program tools and resources

Information, tools, links and resources to support Australia’s National Blood Authority national SCIg program.

Visit tools and resources

SCIg Community of Practice contacts

Contact details of the nurses support hospital based SCIg programs.

View contacts